

UNITED STATES DISTRICT COURT  
DISTRICT OF MASSACHUSETTS

FADI DAHHAN, Individually and on Behalf of All Others Similarly Situated,	)	No. 1:17-cv-10511-IT
	)	
	)	<u>CLASS ACTION</u>
Plaintiffs,	)	
	)	<del>PROPOSED</del> ORDER GRANTING CLASS
vs.	)	REPRESENTATIVE'S UNCONTESTED
	)	MOTION FOR ENTRY OF AN ORDER
OVASCIENCE, INC., et al.,	)	APPROVING NOTICE OF PENDENCY OF
_____	)	CLASS ACTION, NOTICE PROCEDURES,
	)	AND APPOINTMENT OF NOTICE
	)	ADMINISTRATOR

And now this 15<sup>th</sup> day of June, 2020, upon consideration of the Class Representative's Uncontested Motion for Entry of an Order Approving Notice of Pendency of Class Action, Notice Procedures, and Appointment of Notice Administrator (the "Motion") relating to giving notice of pendency of this class action and Class members' rights of exclusion, and there being no objection by the Defendants to the Court's entry of this Order, IT IS HEREBY DETERMINED AND ORDERED THAT the Motion is GRANTED as follows:

1. The Proposed Notice of Pendency of Class Action (the "Printed Notice"), the proposed Summary Notice of Pendency of Class Action (the "Summary Notice"), and the proposed Press Release ("Press Release"), all of which are attached to this Order as Exhibits "A," "B," and "C," respectively (collectively, the "Notice"), are found to comport with the mandates of Rule 23(c)(2)(B) of the Federal Rules of Civil Procedure in that the Notice plainly states the nature of the action, the definition of the Class certified, and the Class claims, and, advises each member of the Class that:

- (a) the Court will exclude from the Class any member who requests exclusion by a specified date;
- (b) the time and manner for requesting exclusion;
- (c) any judgment in this litigation, whether favorable or not, will include all members who do not request exclusion and is binding; and
- (d) any member who does not request exclusion may, if the member desires, enter an appearance through counsel.

2. Counsel for the Class Representative shall cause the Printed Notice to be mailed to all potential members of the Class who can be identified through reasonable effort, cause the Summary Notice to be published once in the national edition of the Investor's Business Daily, and cause the Press Release to be issued over *PR Newswire*. The Printed Notice and the Summary Notice shall also be posted on a website established for this class action by Gilardi & Co. LLC ("Gilardi") (which will serve as the Notice Administrator, *see infra*). The Court finds that the foregoing meets the requirements of Rule 23 of the Federal Rules of Civil Procedure, due process, and any other applicable law, and constitutes the best notice practicable under the circumstances and shall constitute due and sufficient notice to all persons and entities entitled thereof.

3. Defendants, through their counsel, have agreed that within ten (10) calendar days of entry of this Order, they will make best reasonable efforts to provide Class counsel with an electronic copy of the most recent complete mailing list in Defendants' possession and control, to the extent one exists, of all OvaScience, Inc. shareholders of record during the period between December 17, 2014 and September 28, 2015, inclusive (the "Class Period"), which list shall be turned over to the Notice Administrator to facilitate prompt and efficient mailing of the Printed Notice. This list will be submitted to the National Change of Address registry maintained by the United States Postal Service requesting updated address information. Any updated address

information will be appended to the data file used to complete the mailing of the Notice. Defendants' provision of the aforementioned list shall not waive or otherwise limit the right or ability of Defendants to challenge or object to the inclusion of any specific individual or entity in the Class.

4. Class Counsel is hereby authorized to retain Gilardi as the Notice Administrator. The Notice Administrator shall supervise and administer the Notice procedure as more fully set forth below:

(a) Not later than 21 days after entry of this Order, Class Counsel, through the Notice Administrator, shall cause a copy of the Printed Notice, substantially in the form submitted to the Court and conformed as needed to comport with this Order, to be mailed by first class mail to all Class members who can be identified with reasonable effort appearing on the mailing list and posted on a website established by Gilardi for this litigation;

(b) Within seven (7) calendar days of mailing of the Printed Notice, Class Counsel, through the Notice Administrator, shall cause the Summary Notice, substantially in the form submitted to the Court, to be published once in the national edition of *Investor's Business Daily* and as a press release substantially in the form submitted to the Court, over *PR Newswire*. The Summary Notice shall also be posted on a website for the class action established and maintained by Gilardi; and

(c) Class Counsel shall serve on Defendants' counsel and file with the Court, proof, by affidavit or declaration, of such mailing and publishing.

5. The Notice Administrator shall use reasonable efforts to give notice to omnibus account or nominee owners such as brokerage firms and other persons or entities who purchased OvaScience, Inc. shares as record owners but not as beneficial owners. To the extent the beneficial account holders are not known or readily available, nominee owners who purchased, acquired, or

held stock for the benefit of another person during the Class Period shall be requested to send the Printed Notice to all such beneficial owners within seven days after receipt thereof, or to send a list of names and addresses of such beneficial owners to the Notice Administrator within seven days of receipt thereof, in which event the Notice Administrator shall promptly mail the Printed Notice to such beneficial owners and update the electronic mailing list. Nominee owners who elect to send the Printed Notice to their beneficial owners shall send a statement to the Notice Administrator confirming that the mailing was made as directed. Additional copies of the Printed Notice shall be made available to any record holder requesting the Printed Notice for the purpose of distribution to beneficial owners. Such record holders shall be reimbursed by Class Counsel, upon receipt by the Notice Administrator of proper documentation, for the reasonable expense of sending the Printed Notice to beneficial owners. The Notice Administrator will, contemporaneously with the mailing of the Notices, send a letter in the form set out in Exhibit "D" attached to this Order specifically requesting the brokerage firms, banks, and other nominees to, within seven days of receipt of the letter and Printed Notice: (a) supply an Excel file, text file, or other compatible data format containing the names and mailing addresses of Class members; (b) indicate that they will mail the Printed Notices themselves and identify how many Printed Notices they require to complete the mailing; or (c) indicate they have no records of Class members as described in the Printed Notice in this litigation. Copies of the Printed Notice shall also be posted on the website established and maintained for the class action by the Notice Administrator.

6. Any person falling within the definition of the Class shall be bound by all determinations and judgments in the above-captioned action, whether favorable or unfavorable to the Class, unless such person requests exclusion from the Class in a timely and proper manner, as hereinafter provided. A Class member wishing to make such a request for exclusion shall mail the request by first class mail postmarked no later than 60 days following the initial mailing described

in Paragraph 4(a) above to the address designated in the Printed Notice. Such request for exclusion shall clearly indicate the name and address of the person or entity seeking exclusion from the Class in the class action, and a clear indication of the intention to seek exclusion from the Class. Class members requesting exclusion from the Class shall not be entitled to any recovery that might be obtained in the above-captioned action, or bound by any Court orders or judgments in the above-captioned action.

7. Any member of the Class may enter an appearance in the above-captioned action, at their own expense, individually or through counsel of their own choice. If they do not enter an appearance, they will be represented by Class Counsel.

IT IS SO ORDERED:

DATED: June 15, 2020

  
\_\_\_\_\_  
THE HON. INDIRA TALWANI  
UNITED STATES DISTRICT JUDGE

**EXHIBIT “A”**

UNITED STATES DISTRICT COURT  
DISTRICT OF MASSACHUSETTS

FADI DAHHAN, Individually and on Behalf	)	No. 1:17-cv-10511-IT
of All Others Similarly Situated,	)	
	)	<u>CLASS ACTION</u>
Plaintiffs,	)	
	)	
vs.	)	PRINT NOTICE
	)	
OVASCIENCE, INC., et al.,	)	
	)	
Defendants.	)	
	)	
_____	)	

**NOTICE OF PENDENCY OF CLASS ACTION**

**THIS NOTICE MAY AFFECT YOUR RIGHTS – PLEASE READ IT CAREFULLY:**

**TO: PERSONS OR ENTITIES WHO PURCHASED OR OTHERWISE ACQUIRED THE PUBLICLY TRADED COMMON STOCK OF OVASCIENCE, INC. (“OVASCIENCE”), BETWEEN DECEMBER 17, 2014 AND SEPTEMBER 28, 2015, INCLUSIVE (“CLASS PERIOD”). EXCLUDED FROM THE CLASS ARE DEFENDANTS, THE OFFICERS AND DIRECTORS OF THE COMPANY, AT ALL RELEVANT TIMES, MEMBERS OF THEIR IMMEDIATE FAMILIES AND THEIR LEGAL REPRESENTATIVES, HEIRS, SUCCESSORS, OR ASSIGNS, AND ANY ENTITY IN WHICH DEFENDANTS HAVE OR HAD A CONTROLLING INTEREST.**

**THIS NOTICE OF PENDENCY OF CLASS ACTION DESCRIBES YOUR RIGHTS AS A CLASS MEMBER WITH RESPECT TO THE CERTIFIED CLASS ACTION AGAINST OVASCIENCE, INC., MICHELLE DIPP, M.D., Ph.D., AND JEFFREY E. YOUNG.**

The purpose of this Notice is to advise you that:

1. Presently pending before the United States District Court for the District of Massachusetts (the “Court”) is a consolidated securities case captioned *Dahhan v. OvaScience, Inc.* No. 1:17-cv-10511-IT. Pursuant to orders dated May 8, 2020 and May 18, 2020, the Court certified this

securities case as a class action to proceed on behalf of the Class. Lead Plaintiff Freedman Family Investments LLC has been appointed Class Representative.

2. Pursuant to the May 8, 2020 and May 18, 2020 orders, the questions of law and fact common to the Class include claims, issues or defenses regarding whether: Defendants made material omissions and issued materially false and misleading statements in statements distributed to all the class members during the class period resulting in an artificially inflated stock price.

3. If you do not wish to remain a member of the Class described above, you must mail a written request for exclusion from the class action to the address set forth below, postmarked no later than [date 60 days from mailing notice], 2020.

4. This notice is not an expression of the Court of any opinion regarding the merits of any of the claims or defenses asserted by the parties.

## **II. NATURE AND STATUS OF THE LITIGATION**

5. The above-captioned litigation is pending in the United States District Court for the District of Massachusetts.

6. The Amended Class Action Complaint (the “Complaint”) alleges that Defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 by knowingly or recklessly misrepresenting and concealing material facts during the Class Period regarding the efficacy and commercial viability of AUGMENT, which the Complaint alleges was the Company’s only developed treatment. The Complaint alleges that AUGMENT, a new fertility treatment, was intended to improve egg health and address problems in the development of newly formed embryos caused by inadequate energy in the cell division process. The Class Representative seeks, for itself and all other similarly situated persons, compensatory damages, interest, and reasonable costs and expenses, including attorneys’ fees and experts’ fees.

7. More specifically, the Complaint alleges that throughout the Class Period, Defendants made numerous public statements that led investors to believe that AUGMENT worked, that there was significant demand from patients willing to pay for the treatment, that the Company expected to achieve 1,000 commercial cycles in 2015, and that each patient would pay between \$15,000 to \$25,000 for the treatment. The Complaint further alleges that the intended purpose and effect of Defendants’ false and misleading statements was to artificially inflate OvaScience’s stock price throughout the Class Period. The Complaint alleges that the truth regarding AUGMENT’s efficacy, demand, and commercial viability emerged through a series of partial disclosures throughout the Class Period, but was ultimately revealed on September 28, 2015, when the Company disclosed AUGMENT’s commercial prospects in revealing that of the 1,000 commercial cycles it had continuously promised, it had achieved only 35. The Complaint alleges that, as a result, the price of OvaScience shares dropped precipitously, resulting in millions of dollars in investor losses.

8. The sending of this Notice is not an expression by the Court of any opinion on the likelihood of recovery by the Class Representative or on the merits of any defense asserted by Defendants. This Notice is provided only so that you may decide what steps, if any, to take in relation to your continued participation in the Class.

### **III. DEFENDANTS' DENIAL OF LIABILITY**

9. Defendants have denied and continue to deny all claims of wrongdoing or liability against them arising out of any of the conduct, statements, acts, or omissions alleged in the Complaint, including any alleged violations of the federal securities laws or any other legal obligation or duty potentially giving rise to the claims alleged in the Complaint. Defendants have denied and continue to deny each of the claims alleged by the Class Representative on behalf of the Class, including all claims in the Complaint. Defendants believe that they have meritorious defenses to all claims asserted or that could have been asserted based on the allegations of the Complaint. Specifically, Defendant have denied and continue to deny, among other things, that: the alleged misrepresentations or non-disclosures were materially false; the Defendants knowingly or recklessly made false or misleading statements; the Class Representative and the Class have suffered damages; the prices of OvaScience common stock were artificially inflated by reason of the alleged misrepresentations, non-disclosures, or otherwise; and the Class Representative and the Class were otherwise harmed in any other way by the conduct alleged in the Complaint. Moreover, Defendants believe that the evidence developed to date supports their position and assert that the allegations in the Complaint have no merit.

### **IV. YOUR OPTIONS AS A CLASS MEMBER**

10. If you are a member of the Class, you must decide either to stay in this lawsuit or exclude yourself, as described below. You may enter an appearance through your own attorney at your own expense if you so desire. If you are a legal representative for a deceased's estate or an individual who is no longer in charge of his or her own financial matters, and you believe they fall within the definition of the Class, read this notice carefully to decide what steps to take on their behalf.

11. If you are a Class Member, you have a right to stay in the case as a Class Member or be excluded from the lawsuit. You have to decide this very soon.

Option 1. Do Nothing. Stay in the Lawsuit.

You have the right to stay in the lawsuit as a Class Member and await the outcome of the case. You need to do nothing if you wish to remain in this lawsuit. It will cost you nothing. If you decide to stay in the lawsuit as a Class Member, you will be bound by all orders, judgment, and decisions of the Court, whether favorable or unfavorable to the Class. At the end of the case, you may receive money or other benefits as may be awarded as a result of a trial or as a result of a settlement reached between the Class Representative and Defendants, or you may receive nothing. You do not need to do anything to keep open the possibility of getting money or benefits from the lawsuit.

If you stay in the case, the Class Representative will pursue the claims and remedies on your behalf. There is no guarantee that the Class Representative will be successful with its claims and/or win the lawsuit at trial or earlier or later. If the Class is awarded money or benefits, you will be notified about how to make a claim for your share, if any.

12. As a member of the Class, you will be represented by Class Counsel, identified below, and will have no individual liability for attorneys' fees and costs.

**JACK REISE**  
**STEPHEN R. ASTLEY**  
**ELIZABETH A. SHONSON**  
ROBBINS GELLER RUDMAN & DOWD LLP  
120 East Palmetto Park Road, Suite 500  
Boca Raton, Florida 33432  
Telephone: 561/750-3000  
561/750-3364 (fax)

13. More information is available about Class Counsel on the website [www.rgrdlaw.com](http://www.rgrdlaw.com).

14. Class Counsel will represent you as a part of the Class. You will not be individually charged for these lawyers. In the event that Class Representative is successful through trial or settlement, Class Counsel will seek attorneys' fees and expenses. You will not be personally responsible for any fees, costs, or expenses of Class Counsel relating to the prosecution of this lawsuit. You may, if you so desire, enter an appearance through an attorney who will then represent you. You will, however, be responsible for the fees and costs charged by your own attorney appearing on your behalf.

15. Please keep in mind that if you do nothing now and stay in the lawsuit, you will give up your rights to sue Defendants separately in another lawsuit regarding legal claims that are, or could have been, part of this lawsuit, and your rights to recover in other lawsuits involving Defendants may be impacted. You may also forgo your right to pursue claims based on alternative legal theories in favor of the theories being pursued in this case. You waive your right to bring a separate lawsuit if you do not exclude yourself from this case. If you stay in the case, you will be legally bound by all of the orders that the Court issues in this case, including final judgment.

Option 2. Exclude Yourself from the Lawsuit.

16. Alternatively, you have the right to not be part of this lawsuit by excluding yourself or "opting out" of the Class. If you wish to exclude yourself, you must do so on or before [date 60 days after mailing notice] as described below. If you exclude yourself, you give up your right to receive any money or other benefits awarded in this case, and you will not be and do not wish to be bound by future orders of the Court, whether favorable or unfavorable to you and/or the Class. Additionally, if you exclude yourself from the Class, you will keep your rights, if any, to sue Defendants separately in another lawsuit and bring the same legal claims that are part of this lawsuit. Class Members will not have another opportunity to exclude themselves or otherwise opt out of this Litigation. If you wish to pursue your own lawsuit, you will need to exclude yourself and hire and pay your own lawyer. If you choose this option, you should be aware that your claims may be time barred. You should seek legal advice to determine if your claims would be barred by the applicable statutes of limitations or repose.

Do not request exclusion if you wish to be a Class Member in this litigation.

17. If you wish to be excluded, you must submit a written request for exclusion from the Class, addressed to:

OvaScience Securities Litigation  
PO Box 43312  
Providence, RI 02940-3312

18. THE REQUEST FOR EXCLUSION MUST BE POSTMARKED ON OR BEFORE [date 60 days after mailing notice], and must clearly identify the name and address of the person seeking exclusion, the number of shares of OvaScience publicly traded common stock purchased or otherwise acquired between December 17, 2014 and September 28, 2015, inclusive, be signed, and clearly state that the person requests to be excluded from the Class. If you are signing on behalf of the Class Member (such as an estate or an incompetent person), or as a legal representative, please include your full name and the basis for your authority.

A REQUEST FOR EXCLUSION SHALL NOT BE EFFECTIVE UNLESS IT IS POSTMARKED WITHIN THE TIME AND SUBMITTED IN THE MANNER PROVIDED FOR ABOVE.

IF YOU DO NOT EXCLUDE YOURSELF BY THE DEADLINE ABOVE, YOU WILL REMAIN PART OF THE CLASS AND BE BOUND BY THE ORDERS OF THE COURT IN THIS LAWSUIT, INCLUDING FINAL JUDGMENT, WHETHER OR NOT IT IS FAVORABLE TO CLASS REPRESENTATIVE AND YOU.

#### **V. SECURITIES BROKERS AND NOMINEES**

19. Brokers and nominees who purchased or otherwise acquired OvaScience publicly traded common stock between December 17, 2014 and September 28, 2015, inclusive for the beneficial ownership of another are requested to send a list of the names and addresses of such beneficial owners to Gilardi & Co. LLC (“Gilardi,” “Claims Administrator,” or “Notice Administrator”) at the following address no later than seven (7) days after receipt of Notice of this Litigation:

OvaScience Securities Litigation  
PO Box 43312  
Providence, RI 02940-3312

20. The Notice Administrator will thereafter mail copies of this Notice directly to all such beneficial owners. Class Counsel will reimburse the reasonable and actually incurred costs of preparing a list of the names and addresses of such beneficial owners. Brokers and nominees that prefer to mail Notices themselves may request the required number of Notices from the Notice Administrator, and Class Counsel will reimburse the reasonable and actually incurred costs of mailing such Notice.

#### **VI. FURTHER INFORMATION**

21. If you have any questions, please contact the Notice Administrator at [info@ovasciencesecuritieslitigation.com](mailto:info@ovasciencesecuritieslitigation.com) or 1-866-757-7818.

22. This Notice does not fully describe all of the claims and contentions of the parties. Complete copies of the pleadings, orders, and other documents filed in this litigation may be examined and copied at any time during regular office hours at the office of the Clerk of the Court, United States District Court for the District of Massachusetts, 1 Courthouse Way, Boston, Massachusetts 02210. In addition, certain of these documents are also available for viewing at [www.ovasciencesecuritieslitigation.com](http://www.ovasciencesecuritieslitigation.com).

PLEASE DO NOT CONTACT THE COURT OR THE CLERK'S OFFICE REGARDING EXPLANATION OF THIS NOTICE

Dated: \_\_\_\_\_, 2020

BY ORDER OF THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF MASSACHUSETTS

**EXHIBIT “B”**

UNITED STATES DISTRICT COURT  
DISTRICT OF MASSACHUSETTS

FADI DAHHAN, Individually and on Behalf of All Others Similarly Situated,	)	No. 1:17-cv-10511-IT
	)	
	)	<u>CLASS ACTION</u>
Plaintiffs,	)	
	)	
vs.	)	SUMMARY PUBLICATION NOTICE
	)	
OVASCIENCE, INC., et al.,	)	
	)	
Defendants.	)	
	)	
_____	)	

**TO: ALL PERSONS OR ENTITIES WHO, BETWEEN DECEMBER 17, 2014 AND SEPTEMBER 28, 2015, INCLUSIVE, PURCHASED OR OTHERWISE ACQUIRED COMMON STOCK OF OVASCIENCE, INC. (THE “CLASS”).**

Currently pending in the United States District Court for the District of Massachusetts, is a class action brought against OvaScience, Inc. (“OvaScience” or the “Company”), Michelle Dipp, M.D., Ph.D., and Jeffrey E. Young (collectively, “Defendants”) to recover damages for those who purchased OvaScience common stock between December 17, 2014 and September 28, 2015, inclusive (the “Class Period”). The lawsuit is captioned *Dahhan v. OvaScience, Inc.*, No. 1:17-cv-10511-IT.

The Amended Class Action Complaint (the “Complaint”) alleges that Defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 by knowingly or recklessly misrepresenting and concealing material facts during the Class Period regarding the efficacy and commercial viability of AUGMENT, which the Complaint alleges was the Company’s only developed treatment. The Complaint alleges that AUGMENT, a new fertility treatment, was intended to improve egg health and address problems in the development of newly formed embryos caused by inadequate energy in the cell division process. More specifically, the Complaint alleges that throughout the Class Period, Defendants made numerous public statements that led investors to believe that AUGMENT worked, that there was significant demand from patients willing to pay for the treatment, that the Company expected to achieve 1,000 commercial cycles in 2015, and that each patient would pay between \$15,000 to \$25,000 for the treatment. The Complaint alleges that Defendants’ alleged conduct caused OvaScience stock to trade at artificially inflated prices during the Class Period and that Lead Plaintiff and members of the Class were damaged as a result. Defendants have denied and continue to deny all claims of wrongdoing

or liability against them arising out of any of the conduct, statements, acts, or omissions alleged in the Complaint, including any alleged violations of the federal securities laws or any other legal obligation or duty potentially giving rise to the claims alleged in the Complaint. Defendants believe that they have meritorious defenses to all claims asserted or that could have been asserted based on the allegations of the Complaint.

Moreover, Defendants believe that the evidence developed to date supports their position and assert that the allegations in the Complaint have no merit.

Lead Plaintiff has been certified by the Court to represent the following Class:

**PERSONS OR ENTITIES WHO PURCHASED OR OTHERWISE ACQUIRED THE PUBLICLY TRADED COMMON STOCK OF OVASCIENCE, INC. (“OVASCIENCE”), BETWEEN DECEMBER 17, 2014 AND SEPTEMBER 28, 2015, INCLUSIVE (“CLASS PERIOD”). EXCLUDED FROM THE CLASS ARE DEFENDANTS, THE OFFICERS AND DIRECTORS OF THE COMPANY, AT ALL RELEVANT TIMES, MEMBERS OF THEIR IMMEDIATE FAMILIES AND THEIR LEGAL REPRESENTATIVES, HEIRS, SUCCESSORS, OR ASSIGNS, AND ANY ENTITY IN WHICH DEFENDANTS HAVE OR HAD A CONTROLLING INTEREST.**

Pursuant to the Court’s May 8, 2020 and May 18, 2020 orders, the questions of law and fact common to the Class include claims, issues or defenses regarding whether: Defendants made material omissions and issued materially false and misleading statements in statements distributed to all the class members during the class period resulting in an artificially inflated stock price.

On \_\_\_\_\_, 2020, a Notice of Pendency of Class Action (the “Notice”) was mailed to persons who purchased OvaScience common stock during the Class Period, as reflected on the books and records of the Company and its transfer agent. The Notice contains important information regarding the rights of Class members, including the right to seek exclusion from the Class and the legal implications and deadline for doing so. If you believe you are a member of the Class as defined above, and if you have not received a copy of the Notice by mail, you are urged to request a copy free of charge by mailing your request to:

OvaScience Securities Litigation  
PO Box 43312  
Providence, RI 02940-3312

You may also download a copy of the Notice at [www.ovasciencesecuritieslitigation.com](http://www.ovasciencesecuritieslitigation.com).

**IF YOU ARE A CLASS MEMBER AND DO NOT EXCLUDE YOURSELF FROM THE CLASS, YOU WILL BE BOUND BY ALL ORDERS AND ANY JUDGMENT IN THE ACTION. TO EXCLUDE YOURSELF FROM THE CLASS, YOU MUST SUBMIT A WRITTEN REQUEST FOR EXCLUSION POSTMARKED ON OR BEFORE [date 60 days from mailing notice], 2020. NO ACTION IS REQUIRED AT THIS TIME TO REMAIN A MEMBER OF THE CLASS.**

If you have any questions, please contact the Notice Administrator at [info@ovasciencesecuritieslitigation.com](mailto:info@ovasciencesecuritieslitigation.com) or 1-866-757-7818.

PLEASE DO NOT CONTACT THE COURT OR THE CLERK'S OFFICE REGARDING EXPLANATION OF THIS NOTICE

Dated: \_\_\_\_\_, 2020

BY ORDER OF THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF MASSACHUSETTS

EXHIBIT "C"

UNITED STATES DISTRICT COURT  
DISTRICT OF MASSACHUSETTS

FADI DAHHAN, Individually and on Behalf	)	No. 1:17-cv-10511-IT
of All Others Similarly Situated,	)	
	)	<u>CLASS ACTION</u>
Plaintiffs,	)	
	)	
vs.	)	PRESS RELEASE ANNOUNCEMENT OF
	)	CLASS PENDENCY
OVASCIENCE, INC., et al.,	)	
_____	)	

PRESS RELEASE

**Notice of Pendency of Class Action Announced by Lead Class Counsel Jack Reise, Stephen R. Astley, and Elizabeth A. Shonson of Robbins Geller Rudman & Dowd LLP in *Dahhan v. OvaScience, Inc., et al.***

Boston, [Date] -- (PRNewswire) – Jack Reise, Stephen R. Astley, and Elizabeth A. Shonson of Robbins Geller Rudman & Dowd LLP, announce class certification has been granted allowing a class of shareholders to proceed in a lawsuit named *Dahhan v. OvaScience, Inc., et al.*

The litigation asserts claims for alleged violations of the federal securities laws against OvaScience, Inc. (“OvaScience” or the “Company”), Michelle Dipp, M.D., Ph.D., and Jeffrey E. Young. On May 8, 2020 and May 18, 2020, the United States District Court for the District of Massachusetts entered orders, pursuant to Rule 23 of the Federal Rules of Civil Procedure, certifying the case to proceed as a class action on behalf of a Class defined as follows:

**PERSONS OR ENTITIES WHO PURCHASED OR OTHERWISE ACQUIRED THE PUBLICLY TRADED COMMON STOCK OF OVASCIENCE, INC. (“OVASCIENCE”), BETWEEN DECEMBER 17, 2014 AND SEPTEMBER 28, 2015, INCLUSIVE (“CLASS PERIOD”). EXCLUDED FROM THE CLASS ARE DEFENDANTS, THE OFFICERS AND DIRECTORS OF THE COMPANY, AT ALL RELEVANT TIMES, MEMBERS OF THEIR IMMEDIATE FAMILIES AND THEIR LEGAL REPRESENTATIVES, HEIRS, SUCCESSORS, OR ASSIGNS, AND ANY ENTITY IN WHICH DEFENDANTS HAVE OR HAD A CONTROLLING INTEREST.**

Lead Plaintiff Freedman Family Investments LLC has been appointed as Class Representative.

IF YOU ARE A MEMBER OF THE CLASS DESCRIBED ABOVE, YOUR RIGHTS MAY BE AFFECTED. On \_\_\_\_\_, 2020, a Notice of Pendency of Class Action (the “Notice”) was mailed to persons who purchased OvaScience common stock during the Class Period, as reflected on the books and records of the Company and its transfer agent. The Notice contains important information regarding the rights of Class members, including the right to seek exclusion from the Class and the legal implications and deadline for doing so. If you believe you are a member of the Class as defined above, and if you have not received a copy of the Notice by mail, you are urged to request a copy free of charge by mailing your request to:

OvaScience Securities Litigation  
PO Box 43312  
Providence, RI 02940-3312

You may also download a copy of the Notice at [www.ovasciencesecuritieslitigation.com](http://www.ovasciencesecuritieslitigation.com).

**IF YOU ARE A CLASS MEMBER AND DO NOT EXCLUDE YOURSELF FROM THE CLASS, YOU WILL BE BOUND BY ALL ORDERS AND ANY JUDGMENT IN THE ACTION. TO EXCLUDE YOURSELF FROM THE CLASS, YOU MUST SUBMIT A WRITTEN REQUEST FOR EXCLUSION POSTMARKED ON OR BEFORE [date 60 days from mailing notice], 2020.**

CLASS MEMBERS SHOULD NOT CONTACT THE COURT OR THE CLERK’S OFFICE REGARDING EXPLANATION OF THIS NOTICE.



3301 Kerner Blvd.  
San Rafael, CA 94901  
P: (415) 458-3015

«PrintedNoticeDate»

«FirstName» «LastName»  
«Company»  
«Addr1»  
«Addr2»  
«City», «State» «ZIP»«FCountry»

**Re: *Dahhan v. OvaScience, Inc.*, No. 1:17-cv-10511-IT (D. Mass)**

Dear «GENDER» «LastName»:

Please find enclosed the Notice of Pendency of Class Action for the *Dahhan v. OvaScience, Inc.* litigation. Please note both the class period and the designated eligible securities described on page one of the Notice, specifically the inclusion of persons or entities who purchased or otherwise acquired the publicly traded common stock of OvaScience, Inc. (“OvaScience” or the “Company”) between December 17, 2014, and September 28, 2015, inclusive (“Class Period”). Excluded from the class are defendants, the officers and directors of the Company, at all relevant times, members of their immediate families and their legal representatives, heirs, successors, or assigns, and any entity in which defendants have or had a controlling interest. In addition, **the Notice provides that the Exclusion Deadline is [date 60 days after mailing notice].**

Please pay particular attention to the “Securities Brokers and Nominees” on page [XX] of the Notice which states, in part: Brokers and nominees who purchased or otherwise acquired OvaScience publicly traded common stock between December 17, 2014 and September 28, 2015, inclusive for the beneficial ownership of another are requested to send a list of the names and addresses of such beneficial owners to Gilardi & Co. LLC (“Gilardi” or the “Notice Administrator”) at the following address no later than seven (7) days after receipt of Notice of this Litigation. . . . The Notice Administrator will thereafter mail copies of this Notice directly to all such beneficial owners. Class Counsel will reimburse the reasonable and actually incurred costs of preparing a list of the names and addresses of such beneficial owners. Brokers and nominees that prefer to mail Notices themselves may request the required number of Notices from the Notice Administrator, and Class Counsel will reimburse the reasonable and actually incurred costs of mailing such Notice.

Additional copies of the appropriate documents may be requested by contacting us at the above address and/or phone number. If we conduct the necessary mailing on your behalf, please submit names and addresses either via email to [Notifications@Gilardi.com](mailto:Notifications@Gilardi.com), via CD Rom to the above address or contact (415) 458-3015 to obtain secure FTP transmission instructions. Mailing labels will be accepted, but you may be requested to provide an additional copy of the address information you send. Do not include any confidential information that should not appear on a mailing label.

The data provided must be in one of the following formats:

- ASCII Fixed Length file
- ASCII Tab Delimited file
- Microsoft Excel spreadsheet

Your request must also specify the case name and Control Total(s) (for example, the total number of name and address records provided) for each file submission. If you have any questions, please email [Notifications@Gilardi.com](mailto:Notifications@Gilardi.com).

Sincerely,

Gilardi and Company, LLC

**Yolanda Sherman**

---

**From:** ECFnotice@mad.uscourts.gov  
**Sent:** Monday, June 15, 2020 11:49 AM  
**To:** CourtCopy@mad.uscourts.gov  
**Subject:** Activity in Case 1:17-cv-10511-IT DAHHAN v. OvaScience, Inc. et al Order on Motion for Miscellaneous Relief

**This is an automatic e-mail message generated by the CM/ECF system. Please DO NOT RESPOND to this e-mail because the mail box is unattended.**

**\*\*\*NOTE TO PUBLIC ACCESS USERS\*\*\*** Judicial Conference of the United States policy permits attorneys of record and parties in a case (including pro se litigants) to receive one free electronic copy of all documents filed electronically, if receipt is required by law or directed by the filer. PACER access fees apply to all other users. To avoid later charges, download a copy of each document during this first viewing. However, if the referenced document is a transcript, the free copy and 30 page limit do not apply.

**United States District Court**

**District of Massachusetts**

### **Notice of Electronic Filing**

The following transaction was entered on 6/15/2020 at 11:49 AM EDT and filed on 6/15/2020

**Case Name:** DAHHAN v. OvaScience, Inc. et al

**Case Number:** [1:17-cv-10511-IT](#)

**Filer:**

**Document Number:** [114](#)

**Docket Text:**

**Judge Indira Talwani: ORDER GRANTING CLASS REPRESENTATIVE'S UNCONTESTED MOTION FOR ENTRY OF AN ORDER APPROVING NOTICE OF PENDENCY OF CLASS ACTION, NOTICE PROCEDURES, AND APPOINTMENT OF NOTICE ADMINISTRATOR. (Attachments: # (1) Exhibit A, # (2) Exhibit B, # (3) Exhibit C, # (4) Exhibit D) (Kelly, Danielle)**

**1:17-cv-10511-IT Notice has been electronically mailed to:**

Joseph P. Curtin [jcurtin@princelobel.com](mailto:jcurtin@princelobel.com)

John F. Sylvia [jfsylvia@mintz.com](mailto:jfsylvia@mintz.com), [Docketing@mintz.com](mailto:Docketing@mintz.com)

Joseph P. Messina [jmessina@PrinceLobel.com](mailto:jmessina@PrinceLobel.com), [dcovino@princelobel.com](mailto:dcovino@princelobel.com)

Adam L. Sisitsky [asisitsky@mintz.com](mailto:asisitsky@mintz.com), [Docketing@mintz.com](mailto:Docketing@mintz.com)

Jack Reise [jreise@rgrdlaw.com](mailto:jreise@rgrdlaw.com), [creynolds@rgrdlaw.com](mailto:creynolds@rgrdlaw.com), [e\\_file\\_fl@rgrdlaw.com](mailto:e_file_fl@rgrdlaw.com), [e\\_file\\_sd@rgrdlaw.com](mailto:e_file_sd@rgrdlaw.com)

Mitchell J. Matorin mmatorin@matorinlawoffice.com, mitchell-matorin-6100@ecf.pacerpro.com

Alan L. Kovacs alankovacs@yahoo.com

Matthew D. Levitt mdlevitt@mintz.com, docketing@mintz.com

Adam R. Doherty adoherty@princeLobel.com, ktarquino@princelobel.com

Stephen R. Astley sastley@rgrdlaw.com, e\_file\_fl@rgrdlaw.com, e\_file\_sd@rgrdlaw.com, evanyi@rgrdlaw.com

Emily Kanstroom Musgrave EKMusgrave@mintz.com

Rebecca L. Zeidel rlzeidel@mintz.com, KMDoherty@mintz.com

Sabrina E. Tirabassi stirabassi@rgrdlaw.com, e\_file\_fl@rgrdlaw.com, e\_file\_sd@rgrdlaw.com, evanyi@rgrdlaw.com, stirabassi@ecf.courtdrive.com

Elizabeth A. Shonson eshonson@rgrdlaw.com

**1:17-cv-10511-IT Notice will not be electronically mailed to:**

The following document(s) are associated with this transaction:

**Document description:**Main Document

**Original filename:**yes

**Electronic document Stamp:**

[STAMP dcecfStamp\_ID=1029851931 [Date=6/15/2020] [FileNumber=8836991-0] [cb97a9fce547f6f06b443f2708480e829fd4183657d65fbe8d08314c19ea8086856b5daa4af1802e2c13595f7584bbc611bbff858ad079fd176fcbcad4ff5448]]

**Document description:**Exhibit A

**Original filename:**yes

**Electronic document Stamp:**

[STAMP dcecfStamp\_ID=1029851931 [Date=6/15/2020] [FileNumber=8836991-1] [924ab274eb49c2c24279d417d68fe6105a085a23d0182ce72a74f73a855991ee71b8760a900df30a78935cb3623f8b09ded4f27e7acf3b5121b0b30d70ebda0c]]

**Document description:**Exhibit B

**Original filename:**yes

**Electronic document Stamp:**

[STAMP dcecfStamp\_ID=1029851931 [Date=6/15/2020] [FileNumber=8836991-2] [52b0304d652a1e7aefb74d7999a2abd6cfe12223c63f6848673bb8c84aedf67c242373775591bd8158e2688c2e901102f66371adb64afe65ad67539f2812a97c]]

**Document description:**Exhibit C

**Original filename:**yes

**Electronic document Stamp:**

[STAMP dcecfStamp\_ID=1029851931 [Date=6/15/2020] [FileNumber=8836991-3] [c9f5f2ff69c947b4aab46ec50111f67bfd9f3ef769490c1e059d807d087562137480cd61f0812ffd0353c3eee81e81bb76cc9925003e9827b225b346b9d1a527]]

**Document description:**Exhibit D

**Original filename:**yes

**Electronic document Stamp:**

[STAMP dcecfStamp\_ID=1029851931 [Date=6/15/2020] [FileNumber=8836991-4  
] [af468d52f8c3e79d09254e6bb1902c79722ea5395a09b3c81e34c9abb2963601e2c  
bcc5ba81e877ecd7235b6aade040f3d37112b33e1dd707d9167a2367c77ee]]